Literature DB >> 28731277

TNF-α-induced NF-κB activation promotes myofibroblast differentiation of LR-MSCs and exacerbates bleomycin-induced pulmonary fibrosis.

Jiwei Hou1,2, Tan Ma1,2, Honghui Cao1,2, Yabing Chen1,2, Cong Wang1,2, Xiang Chen1,2, Zou Xiang3, Xiaodong Han1,2.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and irreversible lung disease of unknown cause. It has been reported that both lung resident mesenchymal stem cells (LR-MSCs) and tumor necrosis factor-α (TNF-α) play important roles in the development of pulmonary fibrosis. However, the underlying connections between LR-MSCs and TNF-α in the pathogenesis of pulmonary fibrosis are still elusive. In this study, we found that the pro-inflammatory cytokine TNF-α and the transcription factor nuclear factor kappa B (NF-κB) p65 subunit were both upregulated in bleomycin-induced fibrotic lung tissue. In addition, we discovered that TNF-α promotes myofibroblast differentiation of LR-MSCs through activating NF-κB signaling. Interestingly, we also found that TNF-α promotes the expression of β-catenin. Moreover, we demonstrated that suppression of the NF-κB signaling could attenuate myofibroblast differentiation of LR-MSCs and bleomycin-induced pulmonary fibrosis which were accompanied with decreased expression of β-catenin. Our data implicates that inhibition of the NF-κB signaling pathway may provide a therapeutic strategy for pulmonary fibrosis, a disease that warrants more effective treatment approaches.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  NF-κB signaling; idiopathic pulmonary fibrosis (IPF); lung resident mesenchymal stem cells (LR-MSCs); myofibroblast differentiation; tumor necrosis factor-α (TNF-α)

Mesh:

Substances:

Year:  2017        PMID: 28731277     DOI: 10.1002/jcp.26112

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  40 in total

Review 1.  Lung-resident mesenchymal stromal cells are tissue-specific regulators of lung homeostasis.

Authors:  Stefanie Noel Sveiven; Tara M Nordgren
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-05-13       Impact factor: 5.464

2.  Tumor necrosis factor-α coordinates with transforming growth factor-β1 to induce epithelial-mesenchymal transition and migration via the NF-κB/NOX4 pathway in bronchial epithelial cells.

Authors:  Ke Li; Rong Zhou; Mingze Ma; Chaomei Jin; Linlin Jiao; Siyu Zhang; Mei Tian; Fang Zhou
Journal:  Mol Biol Rep       Date:  2022-08-01       Impact factor: 2.742

3.  The identification and validation of hub genes associated with advanced IPF by weighted gene co-expression network analysis.

Authors:  Lingyi Liu; Yanru Yang; Xin Han; Jiwei Hou
Journal:  Funct Integr Genomics       Date:  2022-09-15       Impact factor: 3.674

4.  Modeling Kaempferol as a Potential Pharmacological Agent for COVID-19/PF Co-Occurrence Based on Bioinformatics and System Pharmacological Tools.

Authors:  Yong Jiang; Yi-Zi Xie; Chen-Wen Peng; Kai-Nan Yao; Xue-Ying Lin; Shao-Feng Zhan; Hong-Fa Zhuang; Hui-Ting Huang; Xiao-Hong Liu; Xiu-Fang Huang; Hang Li
Journal:  Front Pharmacol       Date:  2022-06-08       Impact factor: 5.988

5.  Endoplasmic reticulum stress modulates the fate of lung resident mesenchymal stem cell to myofibroblast via C/EBP homologous protein during pulmonary fibrosis.

Authors:  Xiaoyu Yang; Wei Sun; Xiaoyan Jing; Qian Zhang; Hui Huang; Zuojun Xu
Journal:  Stem Cell Res Ther       Date:  2022-06-28       Impact factor: 8.079

6.  The Shh/Gli signaling cascade regulates myofibroblastic activation of lung-resident mesenchymal stem cells via the modulation of Wnt10a expression during pulmonary fibrogenesis.

Authors:  Honghui Cao; Xiang Chen; Jiwei Hou; Cong Wang; Zou Xiang; Yi Shen; Xiaodong Han
Journal:  Lab Invest       Date:  2019-09-20       Impact factor: 5.662

7.  A role for TNF-α in alveolar macrophage damage-associated molecular pattern release.

Authors:  Morgan K Collins; Abigail M Shotland; Morgan F Wade; Shaikh M Atif; Denay K Richards; Manolo Torres-Llompart; Douglas G Mack; Allison K Martin; Andrew P Fontenot; Amy S McKee
Journal:  JCI Insight       Date:  2020-05-07

8.  The heterodimer S100A8/A9 is a potent therapeutic target for idiopathic pulmonary fibrosis.

Authors:  Kota Araki; Rie Kinoshita; Nahoko Tomonobu; Yuma Gohara; Shuta Tomida; Yuta Takahashi; Satoru Senoo; Akihiko Taniguchi; Junko Itano; Ken-Ichi Yamamoto; Hitoshi Murata; Ken Suzawa; Kazuhiko Shien; Hiromasa Yamamoto; Mikio Okazaki; Seiichiro Sugimoto; Kouichi Ichimura; Masahiro Nishibori; Nobuaki Miyahara; Shinichi Toyooka; Masakiyo Sakaguchi
Journal:  J Mol Med (Berl)       Date:  2020-11-09       Impact factor: 4.599

9.  Potential Mechanism Prediction of Herbal Medicine for Pulmonary Fibrosis Associated with SARS-CoV-2 Infection Based on Network Analysis and Molecular Docking.

Authors:  Xuedong An; Yuqing Zhang; Shenghui Zhao; Liyun Duan; Yingying Duan; Fengmei Lian; Xiaolin Tong
Journal:  Front Pharmacol       Date:  2021-04-12       Impact factor: 5.810

Review 10.  Development of antifibrotic therapy for stricturing Crohn's disease: lessons from randomized trials in other fibrotic diseases.

Authors:  Si-Nan Lin; Ren Mao; Chenchen Qian; Dominik Bettenworth; Jie Wang; Jiannan Li; David H Bruining; Vipul Jairath; Brian G Feagan; Min-Hu Chen; Florian Rieder
Journal:  Physiol Rev       Date:  2021-09-27       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.